Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has declared a quarterly dividend of 24.8 cents per share of common stock. The dividend will be paid on October 22, 2025, to shareholders of record as of September 30, 2025. Future dividend payments remain subject to board approval.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Bank of America Global Healthcare Conference in London. The presentation is scheduled for September 25, 2025, from 9:50-10:30 AM BST. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has achieved the highest level of My Green Lab Certification—Green level—at its Refurbishment Centers in Delaware, USA, and Singapore. The centers scored 90% and 87% respectively in rigorous sustainability assessments across 12 critical categories.
The certification highlights Agilent's Certified Pre-Owned (CPO) program, which restores used instruments to factory-grade condition, supporting a circular lab economy through trade-in and buy-back options. Approximately 50% of refurbishment team members have become My Green Lab Ambassadors, demonstrating the company's commitment to sustainability.
TORM plc (NASDAQ: TRMD) announced that Hafnia Limited will acquire approximately 14.1 million A shares (14.45% of TORM's issued share capital) from Oaktree Capital Management. The transaction is valued at USD 22 per share, totaling USD 311.4 million.
The share purchase completion is subject to several conditions, including regulatory approvals, satisfaction of certain covenants, and the appointment of a new independent board chairman. TORM clarified that it was not involved in the transaction and has no additional information at this time.
Agilent Technologies (NYSE: A) announced its participation as a premium sponsor at the European Congress of Pathology (ECP) 2025 in Vienna, Austria, from September 6-10, 2025. The company will showcase the European launch of its expanded Dako Omnis Family of instruments, including the Dako Omnis 110, 165, and 165 Duo models.
The event will feature live demonstrations, expert sessions, and educational symposia focusing on diagnostic excellence and workflow optimization. Visitors can explore Agilent's Digital Pathology solutions and participate in PD-L1 CPS scoring sessions at booth #18.
Agilent Technologies (NYSE: A) has achieved a significant regulatory milestone as its MMR IHC Panel pharmDx (Dako Omnis) received European IVDR certification as a class C companion diagnostic test for colorectal cancer. The panel is specifically designed to identify mismatch repair (MMR) deficient CRC patients who may be eligible for treatment with OPDIVO® in combination with YERVOY®.
The diagnostic panel is uniquely positioned as the only companion diagnostic IHC panel IVDR approved for this specific treatment combination in colorectal cancer patients. The test works by detecting the loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in tissue samples, helping identify patients who may respond better to immunotherapy.
Agilent Technologies (NYSE: A) reported strong Q3 2025 financial results with revenue of $1.74 billion, representing 10.1% reported growth and 6.1% core growth year-over-year. The company achieved GAAP EPS of $1.18 (up 22%) and non-GAAP EPS of $1.37 (up 4%).
All three business segments showed growth: Life Sciences and Diagnostics Markets Group revenue increased 14% to $670 million, Agilent CrossLab Group grew 8% to $744 million, and Applied Markets Group rose 7% to $324 million.
Agilent raised its full-year 2025 outlook, projecting revenue between $6.91-6.93 billion (6.2-6.5% growth) and non-GAAP EPS of $5.56-5.59. Q4 2025 revenue is expected at $1.822-1.842 billion with non-GAAP EPS of $1.57-1.60.
Helzberg, a subsidiary of Berkshire Hathaway (NYSE:BRK), has announced a national partnership with Big Brothers Big Sisters of America (BBBSA) ahead of Big Brothers Big Sisters Month in September 2025. The collaboration combines financial investment, volunteer engagement, and career exploration opportunities to enhance youth mentorship nationwide.
The partnership launched in Kansas City with BBBSA's Diamond Anniversary celebration at Kauffman Stadium and will continue with various events including a special gathering at the KC Current match on August 30. Helzberg's nationwide network of associates will participate in volunteer efforts including career day mentoring and Pack + Give Back events across key markets.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Wells Fargo Healthcare Conference. The presentation is scheduled for September 3, 2025, from 11:00 to 11:35 AM ET in Everett, Massachusetts. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has received FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic test for colorectal cancer. The test identifies mismatch repair deficient (dMMR) colorectal cancer patients eligible for treatment with Bristol Myers Squibb's Opdivo alone or in combination with Yervoy.
The panel is the only FDA-approved companion diagnostic IHC panel for this specific purpose and is exclusively designed for use with Agilent's Dako Omnis automated staining solution. The test detects loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in colorectal cancer tissue, helping identify patients who may respond better to immunotherapy.